Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEW RECHALLENGE: mFOLFOX6 vs FOLFIRI for Colorectal Cancer Recurrence
NCT05362617Phase 3Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FOLFIRI in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 6 weeks. Status: unknown.
02
Drugs
FOLFIRI
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05362617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362617.